TerminatedNot Applicable

Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

Stopped: Insufficient participant enrollment

United States100 participantsStarted 2023-03-17

Plain-language summary

The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years; AND * HIV infection with CD4 count \< 200 cells/uL; AND * Probable or confirmed mpox (does NOT need to be a new diagnosis); AND * Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control Exclusion Criteria: * Inability of the individual or appropriate proxy to provide informed consent. * In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation.

What they're measuring

Monkeypox viral persistence

Timeframe: While hospitalized, for up to 12 months

Monkeypox viral viability

Timeframe: While hospitalized, for up to 12 months

Immune response

Timeframe: While hospitalized, for up to 12 months

Trial details

NCT IDNCT06045923

SponsorCenters for Disease Control and Prevention

Sponsor typeFED

Study typeOBSERVATIONAL

Primary completion2026-01-01

View on ClinicalTrials.gov More Monkeypox trials